Show simple item record

dc.contributor.authorAdams, Richard
dc.contributor.authorBrown, Ewan
dc.contributor.authorBrown, Louise
dc.contributor.authorButler, Rachel
dc.contributor.authorFalk, Stephen
dc.contributor.authorFisher, David
dc.contributor.authorKaplan, Richard
dc.contributor.authorQuirke, Phil
dc.contributor.authorRichman, Susan
dc.contributor.authorSamuel, Leslie
dc.contributor.authorSeligman, Jenny
dc.contributor.authorSeymour, Matt
dc.contributor.authorShui, Kai Keen
dc.contributor.authorWasan, Harpreet
dc.contributor.authorWilson, Richard
dc.contributor.authorMaughan, Tim
dc.date.accessioned2018-04-02T15:24:06Z
dc.date.available2018-04-02T15:24:06Z
dc.date.issued2018-03
dc.identifier.citationAdams , R , Brown , E , Brown , L , Butler , R , Falk , S , Fisher , D , Kaplan , R , Quirke , P , Richman , S , Samuel , L , Seligman , J , Seymour , M , Shui , K K , Wasan , H , Wilson , R & Maughan , T 2018 , ' Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2–3 randomised trial ' , The Lancet Gastroenterology & Hepatology , vol. 3 , no. 3 , pp. 162–171 . https://doi.org/10.1016/S2468-1253(17)30394-1en
dc.identifier.otherPURE: 117867917
dc.identifier.otherPURE UUID: 7799814c-a837-42b2-8a2d-070c17868281
dc.identifier.otherScopus: 85042363378
dc.identifier.otherORCID: /0000-0002-8402-8670/work/50559777
dc.identifier.urihttp://hdl.handle.net/2164/10279
dc.descriptionThis study was funded by the UK Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme; Cancer Research UK; NIHR Clinical Trials Research Network; Health and Care Research Wales (and equivalent in devolved nations); and AstraZeneca Drug Supply and Distribution. PQ, MS, and SR received programme grant support from Yorkshire Cancer Research. PQ is an NIHR Senior Investigator at the Department of Pathology Cardiff and Vale University Health Board, All Wales Genetics Laboratories, Wales Cancer Bank. The MRC Clinical Trials Unit at University College London receives funding from the MRC (programme grant MC_UU_12023/20).en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofThe Lancet Gastroenterology & Hepatologyen
dc.rights© The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/en
dc.subjectcolorectal canceren
dc.subjectbiomarkersen
dc.subjecttherapeutic efficacyen
dc.subjectEGFR inhibitorsen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectMedical Research Council (MRC)en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleInhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2–3 randomised trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S2468-1253(17)30394-1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record